Forbion Portfolio Company Orbis Medicines named in 2025 Endpoints 11
Orbis Medicines, a Forbion portfolio company, has been recognized on the prestigious Endpoints 11 list of the year’s most promising private biopharma innovators.
Orbis is pioneering macrocycle drugs, ring-shaped molecules that combine the potency of biologics with the convenience of a pill. Founded in 2021 from EPFL research in Switzerland, the company uses synthetic amino acids, high-throughput screening, and generative AI to develop oral therapies for chronic diseases that are typically treated with injectable antibodies.